HCA Healthcare appoints Chad Wasserman as new chief information officer

The largest health system in the U.S. has a new chief information officer, as HCA Healthcare has introduced three-decade company veteran Chad Wasserman as its new senior VP and CIO.

Wasserman assumed his new role at the start of the month, succeeding P. Martin “Marty” Paslick, who retires after a 38-year run with the organization. Previously the senior VP and COO of HCA’s IT Group, Wasserman will now lead the full team of over 6,700 IT staff in providing the organization’s infrastructure, cloud services, automation, data engineering, software development and clinical technology initiatives.

"Throughout his career, Chad has demonstrated a strong ability to drive technology solutions across a wide range of business areas,” says Sam Hazen, CEO of HCA Healthcare, in an announcement.

Under retiring CIO Paslick, HCA developed one of the largest iOS platforms in the country and launched a partnership with Google Cloud.

IT security continues to be a growing concern in healthcare, as evidenced by HCA’s own brush with hacked data last year.

“Marty’s service to HCA Healthcare has been revolutionary for the company and has set the course for our technology agenda,” Hazen remarks.

Evan Godt
Evan Godt, Writer

Evan joined TriMed in 2011, writing primarily for Health Imaging. Prior to diving into medical journalism, Evan worked for the Nine Network of Public Media in St. Louis. He also has worked in public relations and education. Evan studied journalism at the University of Missouri, with an emphasis on broadcast media.

Around the web

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.